What this study adds
- PD-1-targeted immunotherapy with Toripalimab, Camrelizumab or
Sintilimab yielded a promising outcome in Chinese HBV patients with
HCC.
- PD-1 therapy was well tolerated generally and had manageable side
effects, which is worth of popularization and application in clinical
practice.